Safety Center
Educational information about peptide quality, safety considerations, and general guidance. This is not medical advice.
High-Priority Safety Signals
Grey-market quality concerns
Retatrutide is not approved for commercial sale. Grey-market versions are not manufactured under GMP conditions and may contain incorrect quantities, impurities, or degradation products. No regulatory oversight of these products exists.
FDA compounding ban (2023)
In 2023, the FDA added BPC-157 to the list of substances that cannot be used in compounding under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. This means licensed compounding pharmacies in the US cannot legally prepare BPC-157 for patients. Products available in the grey market lack pharmaceutical quality controls.
Thyroid C-cell tumors (FDA boxed warning)
All GLP-1RA labels, including semaglutide, carry a boxed warning regarding risk of thyroid C-cell tumors based on rodent studies. Semaglutide caused dose-dependent thyroid C-cell tumors in rats and mice. While relevance to humans is uncertain, semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
Thyroid C-cell tumors (FDA boxed warning)
Tirzepatide carries the same boxed warning as other GLP-1RAs regarding thyroid C-cell tumors. Rodent carcinogenicity studies showed dose-dependent increases in thyroid C-cell tumors. Contraindicated in patients with a personal or family history of MTC or MEN2.
Thyroid C-cell tumors (FDA boxed warning)
Liraglutide carries a boxed warning for thyroid C-cell tumors based on rodent findings. The LEADER trial did not show an increased signal for MTC in humans over 3.8 years, but long-term surveillance continues. Contraindicated in patients with MTC history or MEN2.
Insulin-induced severe hypoglycemia (FDA boxed warning)
The Symlin (pramlintide) label carries a boxed warning for increased risk of insulin-induced severe hypoglycemia, particularly in type 1 diabetes. Hypoglycemia can occur within 3 hours of injection. Mealtime insulin doses must be reduced by 50% when initiating pramlintide. Close glucose monitoring is required during the initial titration period.
Melanoma risk and nevus changes
Melanotan II is a non-selective melanocortin agonist that stimulates melanogenesis independently of UV exposure. Multiple case reports document darkening, enlargement, or dysplastic changes in pre-existing nevi following melanotan II use. There is theoretical concern that stimulating melanocyte activity could accelerate progression of subclinical melanoma. Several dermatological societies have issued warnings against its use. Blood pressure elevation and severe nausea are also common acute adverse effects.
Understanding Peptide Quality
- FDA-approved peptides are manufactured under strict GMP (Good Manufacturing Practice) conditions with verified potency, purity, and sterility.
- Compounded peptides from 503A or 503B pharmacies are subject to some regulatory oversight but vary in quality. The FDA has removed several peptides from the compounding allowed list.
- Grey-market peptides labeled as “research chemicals” or “not for human consumption” have no regulatory quality oversight. Independent testing has shown significant variability in actual peptide content, purity, and the presence of contaminants.
- Third-party certificate of analysis (COA) testing can provide some assurance of purity and potency but does not substitute for GMP manufacturing oversight.
Counterfeit and Mislabeling Risks
- Products may contain less peptide than labeled, degraded peptide, or a completely different substance than advertised.
- Bacterial contamination, endotoxins, and heavy metals have been found in grey-market peptide products in independent testing.
- “Pharmaceutical grade” claims on unregulated products are unverified and should not be taken at face value.
- Products claiming to be “the same as” FDA-approved drugs (e.g., semaglutide, bremelanotide) but sold without a prescription may be counterfeit.
Questions to Ask Your Provider
- What is the regulatory status of this peptide?
- What is the evidence base (human clinical trials vs. preclinical only)?
- Where is the product sourced, and is there a certificate of analysis available?
- What monitoring should be done before and during use?
- What are the known risks and what symptoms should prompt discontinuation?
When to Seek Medical Attention
Seek immediate medical attention if you experience any of the following after using any peptide product:
- Signs of allergic reaction (hives, swelling, difficulty breathing)
- Chest pain or shortness of breath
- Severe abdominal pain or persistent vomiting
- Signs of infection at injection site (increasing redness, warmth, swelling, pus, fever)
- Severe headache, vision changes, or neurological symptoms
- Signs of hypoglycemia (shakiness, confusion, sweating) if using metabolic peptides
This is general health information and not a substitute for professional medical assessment.
Understanding Evidence Grades
Each compound in the PDR is assigned an evidence grade based on the quality and quantity of available clinical evidence.
FDA-approved with multiple well-designed RCTs and post-marketing surveillance data. Mechanism well characterized.
Phase 2/3 clinical trial data in humans. Mechanism characterized. May not yet have regulatory approval or long-term data.
Primarily preclinical data. Limited or no controlled human trials. Mechanism proposed but not fully validated. Commonly seen in grey-market compounds.
Minimal or non-peer-reviewed data. Claims not independently replicated. High uncertainty about efficacy and safety profile.